These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity. Lin J; Sun S; Zhao K; Gao F; Wang R; Li Q; Zhou Y; Zhang J; Li Y; Wang X; Du L; Wang S; Li Z; Lu H; Lan Y; Song D; Guo W; Chen Y; Gao F; Zhao Y; Fan R; Guan J; He W Nat Commun; 2023 Jan; 14(1):224. PubMed ID: 36641456 [TBL] [Abstract][Full Text] [Related]
24. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Pulido J; Pavelko K; Pease L; Melcher A; Vile R Cancer Res; 2010 Jun; 70(11):4539-49. PubMed ID: 20484025 [TBL] [Abstract][Full Text] [Related]
25. ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models. Dong W; van Ginkel JW; Au KY; Alemany R; Meulenberg JJ; van Beusechem VW Hum Gene Ther; 2014 Oct; 25(10):897-904. PubMed ID: 25093639 [TBL] [Abstract][Full Text] [Related]
27. Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity. Garofalo M; Iovine B; Kuryk L; Capasso C; Hirvinen M; Vitale A; Yliperttula M; Bevilacqua MA; Cerullo V Mol Cancer Ther; 2016 Apr; 15(4):651-60. PubMed ID: 26861248 [TBL] [Abstract][Full Text] [Related]
28. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model. Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208 [TBL] [Abstract][Full Text] [Related]
29. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729 [TBL] [Abstract][Full Text] [Related]
30. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Sampath P; Li J; Hou W; Chen H; Bartlett DL; Thorne SH Mol Ther; 2013 Mar; 21(3):620-8. PubMed ID: 23229093 [TBL] [Abstract][Full Text] [Related]
31. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991 [TBL] [Abstract][Full Text] [Related]
32. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Prestwich RJ; Ilett EJ; Errington F; Diaz RM; Steele LP; Kottke T; Thompson J; Galivo F; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA Clin Cancer Res; 2009 Jul; 15(13):4374-4381. PubMed ID: 19509134 [TBL] [Abstract][Full Text] [Related]
33. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy. Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191 [TBL] [Abstract][Full Text] [Related]
34. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy. Zhang L; Hedjran F; Larson C; Perez GL; Reid T Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035 [TBL] [Abstract][Full Text] [Related]
35. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model. Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393 [TBL] [Abstract][Full Text] [Related]
37. ORFV infection enhances CXCL16 secretion and causes oncolysis of lung cancer cells through immunogenic apoptosis. Wang R; Mo J; Luo X; Zhang G; Liu F; Luo S Front Cell Infect Microbiol; 2022; 12():910466. PubMed ID: 35959371 [TBL] [Abstract][Full Text] [Related]
38. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity. Yan Y; Li S; Jia T; Du X; Xu Y; Zhao Y; Li L; Liang K; Liang W; Sun H; Li R Tumour Biol; 2015 Jun; 36(6):4535-43. PubMed ID: 25627006 [TBL] [Abstract][Full Text] [Related]
39. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma. Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179 [TBL] [Abstract][Full Text] [Related]
40. The role of JNK phosphorylation as a molecular target to enhance adenovirus replication, oncolysis and cancer therapeutic efficacy. Wechman SL; Rao XM; Gomez-Gutierrez JG; Zhou HS; McMasters KM Cancer Biol Ther; 2018; 19(12):1174-1184. PubMed ID: 30067431 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]